Oral Interferon-Alpha for Chronic External Otitis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic intractable external otitis in pets, such as dogs and cats, are often invasive, require high concentrations of interferon, and do not achieve complete cure, necessitating a quick-acting and sustained therapeutic agent for effective management.

Innovation Solution

A pharmaceutical composition comprising interferon-α as an active ingredient, administered orally or via oral mucosal or gingival application, using a pharmaceutically acceptable carrier like a chewable tablet or paste, to provide a safer and more effective treatment option for chronic intractable external otitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If interferon is administered invasively at high concentration, then therapeutic effect is improved, but safety and ease of administration deteriorate

Engineering Contradiction:

Improvetherapeutic effectVSAvoidease of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the administration route from invasive (subcutaneous or intravenous) to oral, and reduces the interferon concentration from high to low dose, thereby improving ease of administration while maintaining therapeutic effect through the unique oral bioavailability of interferon-alpha

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the mechanical injection method (subcutaneous or intravenous administration) with oral administration, eliminating the need for invasive procedures and improving ease of use while achieving comparable or better therapeutic outcomes

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If interferon is administered invasively at high concentration, then therapeutic effect is improved, but safety deteriorates

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent reduces the interferon concentration from high to low dose and changes administration from invasive to oral, thereby improving safety by reducing side effects while maintaining therapeutic effectiveness through optimized oral bioavailability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the potential harm of invasive administration and high concentration side effects into benefit by using oral low-dose administration, which reduces harmful effects while maintaining or improving therapeutic outcomes

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Object-generated harmful factors

If conventional treatments are used for chronic intractable external otitis, then symptomatic relief is achieved, but complete cure is difficult

Engineering Contradiction:

Improvesymptom reliefVSAvoidcomplete cure

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent uses oral interferon-alpha as an intermediary substance that addresses the underlying immune dysfunction in chronic intractable external otitis, enabling complete cure rather than just symptomatic relief by modulating the immune response systemically

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP3278812B1Therapeutic effect of oral interferon alpha administration on chronic intractable external otitis

Publication Date: 2022.11.09 HOKUSAN

Figure 1~2
Figure 3
Figure 4

AI summary

The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-α (IFNα) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFNα can give a sufficient effect even when administered in a very small amount.